Ana Bocanegra

Hospital Universitario Puerta de Hierro Majadahonda — Spain

Medicine · Health Sciences

20h-index1.7kcitations68works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(38), Immune cells in cancer(17), Immunotherapy and Immune Responses(16), CAR-T cell therapy research(16), Pancreatic and Hepatic Oncology Research(9)

Publications67 total

A paired study comparing mononuclear cell collection using a new in‐line system with an off‐line extracorporeal photopheresis apheresis system
Transfusion·2025
110MO CD8 T cells are responsible for the PD-1, LAG-3 and CBL-B triple blockade therapeutic antitumor effect
ESMO Open·2024Open Access
4P CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Annals of Oncology·2024Open Access
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
EMBO Molecular Medicine·2024· 14 citedOpen Access
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
British Journal of Cancer·2024· 12 citedOpen Access
Triple-Labeling of Polymer-Coated Quantum Dots and Adsorbed Proteins for Tracing their Fate in Cell Cultures
2024Open Access
Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer
Head & Neck·2023· 6 citedOpen Access
15P CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Annals of Oncology·2023Open Access
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy
Nature Metabolism·2023· 44 citedOpen Access
Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp> / <scp>PD</scp> ‐1 blockade in lung cancer
EMBO Reports·2023· 11 citedOpen Access
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
International Journal of Molecular Sciences·2023· 6 citedOpen Access
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
International Journal of Molecular Sciences·2023· 73 citedOpen Access
PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers
2023· 1 citedOpen Access
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
International Journal of Molecular Sciences·2023· 16 citedOpen Access
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
Oncology and Therapy·2022· 15 citedOpen Access
Cutting-Edge CAR Engineering: Beyond T Cells
Biomedicines·2022· 9 citedOpen Access
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
International Journal of Molecular Sciences·2022· 16 citedOpen Access
Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
Cancers·2022· 13 citedOpen Access
1074P Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy
Annals of Oncology·2022
The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma
Journal of Investigative Dermatology·2022· 27 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

David Escors(46), Grazyna Kochan(45), Hugo Arasanz(42), Luisa Chocarro(38), Ester Blanco(30), Miren Zuazo(25), Miriam Echaide(25), Maider Garnica(24), Leticia Fernández(22), Ruth Vera(20), G. Fernández-Hinojal(16), Ruth Vera(16), Pablo Ramos(16), Sergio Piñeiro‐Hermida(12), Lucía Teijeira(10), Idoia Morilla(10), Joaquín Fernández‐Irigoyen(10), María Gato(9), Enrique Santamaría(9), Karina Ausín(9)